Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

Nature Communications

Volumn 8, Issue , 2017, Pages

  Bradley, Todd ^a   Pollara, Justin ^a   Santra, Sampa ^b   Vandergrift, Nathan ^a   Pittala, Srivamshi ^c   Bailey Kellogg, Chris ^c   Shen, Xiaoying ^a   Parks, Robert ^a   Goodman, Derrick ^a   Eaton, Amanda ^a   Balachandran, Harikrishnan ^b   MacH, Linh V ^b   Saunders, Kevin O ^a   Weiner, Joshua A ^c   Scearce, Richard ^a   Sutherland, Laura L ^a   Phogat, Sanjay ^d   Tartaglia, Jim ^d   Reed, Steven G ^e   Hu, Shiu Lok ^f   Theis, James F ^g   Pinter, Abraham ^g   Montefiori, David C ^a   Kepler, Thomas B ^h   Peachman, Kristina K ^i,j   Rao, Mangala ⁱ   Michael, Nelson L ⁱ   Suscovich, Todd J ^k   Alter, Galit ^k   Ackerman, Margaret E ^c   Moody, M Anthony ^a   Liao, Hua Xin ^a   Tomaras, Georgia ^a   Ferrari, Guido ^a   Korber, Bette T ^l   Haynes, Barton F ^a   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DARTMOUTH COLLEGE   (United States)

^d SANOFI PASTEUR   (France)

^e INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^h BOSTON UNIVERSITY   (United States)

ⁱ WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^j HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^k MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^l LOS ALAMOS NATIONAL LABORATORY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; COMPLEMENT; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANTIBODY; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG DEVELOPMENT; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE; MEMORY CELL; NONHUMAN; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ANIMAL; CYTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MONONUCLEAR CELL; MUTATION; NATURAL KILLER CELL; PHAGOCYTOSIS; PHYLOGENY; PREDICTIVE VALUE; REGRESSION ANALYSIS; SERODIAGNOSIS; SIMIAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; POXVIRIDAE; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; COMPLEMENT SYSTEM PROTEINS; EPITOPES; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MALE; MUTATION; NEUTRALIZATION TESTS; PHAGOCYTOSIS; PHYLOGENY; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 85020430149     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15711     Document Type: Article

References (66)

1. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
2. Robb, M. L. et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet 12, 531-537 (2012).
3. Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665 (2005).
4. Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
5. Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571-576 (2015).
6. Haynes, B. F. et al. Progress in HIV-1 vaccine development. J. Allergy Clin. Immunol. 134, 3-10 quiz 11 (2014).
7. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
8. Montefiori, D. C. et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431-441 (2012).
9. Yates, N. L. et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med. 6, 228ra239 (2014).
10. Zolla-Pazner, S. et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS ONE 9, e87572 (2014).
11. Rolland, M. et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490, 417-420 (2012).
12. Kijak, G. H. et al. Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial. J. Virol. 87, 7265-7281 (2013).
13. Gao, F. et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J. Virol. 70, 7013-7029 (1996).
14. Song, R. J. et al. Molecularly cloned SHIV-1157ipd3N4: a highly replicationcompetent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J. Virol. 80, 8729-8738 (2006).
15. Fischer, W. et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13, 100-106 (2007).
16. Moody, M. A. et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J. Virol. 88, 3329-3339 (2014).
17. Liao, H. X. et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 38, 176-186 (2013).
18. Bonsignori, M. et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86, 4688-4692 (2012).
19. Ferrari, G. et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 85, 7029-7036 (2011).
20. Mayr, L. M., Cohen, S., Spurrier, B., Kong, X. P. & Zolla-Pazner, S. Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. PLoS ONE 8, e70859 (2013).
21. Arthos, J. et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9, 301-309 (2008).
22. Pegu, P. et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 87, 1708-1719 (2013).
23. Vaccari, M. et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J. Virol. 87, 3538-3548 (2013).
24. Barouch, D. H. et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531-539 (2013).
25. Barouch, D. H. et al. Vaccine protection against acquisition of neutralizationresistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
26. Barouch, D. H. et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349, 320-324 (2015).
27. Pollara, J. et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 88, 7715-7726 (2014).
28. Veazey, R. S. et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998).
29. Byrareddy, S. N. et al. Sustained virologic control in SIV+ macaques after antiretroviral and alpha4beta7 antibody therapy. Science 354, 197-202 (2016).
30. Byrareddy, S. N. et al. Targeting alpha4beta7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-Associated lymphoid tissue from infection. Nat. Med. 20, 1397-1400 (2014).
31. Guindon, S. et al. New algorithms and methods to estimate maximumlikelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 59, 307-321 (2010).
32. Lee, H. Y. et al. Modeling sequence evolution in acute HIV-1 infection. J. Theor. Biol. 261, 341-360 (2009).
33. McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
34. Thurmond, J. et al. Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics 24, 1639-1640 (2008).
35. Liao, H. X. et al. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J. Virol. 87, 4185-4201 (2013).
36. Liao, H. X. et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353, 268-282 (2006).
37. Santra, S. et al. Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathogens 11, e1005042 (2015).
38. Bonsignori, M. et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998-10009 (2011).
39. Liao, H. X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013).
40. Shen, X. et al. Vaccine-induced linear epitope-specific antibodies to simian immunodeficiency virus SIVmac239 envelope are distinct from those induced to the human immunodeficiency virus type 1 envelope in nonhuman primates. J. Virol. 89, 8643-8650 (2015).
41. Tomaras, G. D. et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85, 11502-11519 (2011).
42. Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131-146 (2014).
43. Seaman, M. S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439-1452 (2010).
44. Pollara, J. et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79, 603-612 (2011).
45. Koene, H. R. et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90, 1109-1114 (1997).
46. Edmonds, T. G. et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408, 1-13 (2010).
47. Pollara, J. et al. Association of HIV-1 envelope-specific breast milk IgA responses with reduced risk of postnatal mother-to-child transmission of HIV-1. J. Virol. 89, 9952-9961 (2015).
48. Carson, W. E. et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403 (1994).
49. Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8-19 (2011).
50. Tay, M. Z. et al. Antibody-mediated internalization of infectious HIV-1 virions differs among antibody isotypes and subclasses. PLoS Pathogens 12, e1005817 (2016).
51. Brown, E. P. et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 386, 117-123 (2012).
52. Chan, Y. N. et al. IgG binding characteristics of rhesus macaque FcgammaR. J. Immunol. 197, 2936-2947 (2016).
53. Boesch, A. W. et al. Highly parallel characterization of IgG Fc binding interactions. mAbs 6, 915-927 (2014).
54. Chung, A. W. et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6, 228ra238 (2014).
55. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1-22 (2010).
56. Ojala, M. & Garriga, G. C. Permutation tests for studying classifier performance. J. Mach. Learn. Res. 11, 1833-1863 (2010).
57. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B 34, 187-+ (1972).
58. Therneau, T. M. & Grambsch, P. M. Modeling Survival Data: Extending the Cox Model (Springer, 2000).
59. Drasgow, F. Polychoric and polyserial correlations. Encyclopedia Stat. 7, 68-74 (1986).
60. Harrell, Jr. F. E., Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361-387 (1996).
61. Wiehe, K. et al. Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity 41, 909-918 (2014).
62. Kepler, T. B. Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. F1000Res. 2, 103 (2013).
63. Munshaw, S. & Kepler, T. B. SoDA2: a Hidden Markov Model approach for identification of immunoglobulin rearrangements. Bioinformatics 26, 867-872 (2010).
64. Liao, H. X. et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods 158, 171-179 (2009).
65. Liao, H. X. et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 208, 2237-2249 (2011).
66. Peachman, K. K. et al. Identification of new regions in HIV-1 gp120 variable 2 and 3 loops that bind to alpha4beta7 integrin receptor. PLoS ONE 10, e0143895 (2015).